CytoMed Therapeutics is a clinical-stage biopharmaceutical company based in Singapore, developing "off-the-shelf" allogeneic cell therapies for cancer and degenerative diseases. CytoMed's core focus is on gamma delta T cells and NK cells derived from healthy donors, which can be manufactured at scale and used across a broad patient population without requiring patient-specific production. This approach contrasts with approved autologous CAR-T therapies, which are manufactured individually per patient and are expensive to produce. CytoMed's lead program, CTM-N2D, uses donor-derived CAR-gamma delta T cells targeting NKG2D ligands — stress-induced antigens expressed across many cancer types, including solid tumors — and is currently in a Phase I trial at National University Hospital Singapore. Additional pipeline candidates include CTM-GDT (unmodified gamma delta T cells, with a Phase I trial in Malaysia targeted for late 2026), iPSC-gdNKT (iPSC-derived hybrid immune cells, pre-clinical), CTM-MSC (mesenchymal stem cells for degenerative diseases), and CTM-NK (NK cells targeting cancer and immune decline). CytoMed licenses its core IP from A*STAR, Singapore's public R&D agency, and manufactures in-house at a cGMP facility in Johor, Malaysia. The company also operates a cord blood bank in Malaysia, called The Longevity Bank, which supports its R&D supply chain. CytoMed is pre-revenue and funds operations through equity issuance and grants, including co-funding from Singapore's Ministry of Health.